Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers
Stock Information for Oncolytics Biotech Inc.
Loading
Please wait while we load your information from QuoteMedia.